VJHemOnc Podcast
Latest Episodes
A focus on the use of artificial intelligence to personalize blood cancer care
Welcome to the final episode of VJHemOncs Blood Cancer Awareness Month special series! This episode focuses on the role of...
A focus on pediatric leukemias: trials, treatments, & challenges
Welcome to the third episode of VJHemOncs Blood Cancer Awareness Month special series! The focus of this episode is pediatric...
A focus on the psychosocial impacts of living with blood cancer
Welcome to the second episode of VJHemOncs Blood Cancer Awareness Month special series! Todays episode focuses on the psychosocial impacts...
Global perspectives on blood cancers: addressing disparities in awareness, diagnosis, and treatment
Welcome to the first episode of VJHemOncs Blood Cancer Awareness Month special series! This episode focuses on global perspectives of...
Insights into PV and ET: treating the AYA population, defining goals when treating patients, & more
Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms (MPNs) characterized by the overproduction of red blood cells and...
Hemophilia updates from ISTH 2024: ongoing clinical trials, emerging gene therapies & remaining challenges
This weeks VJHemOnc podcast brings you updates in hemophilia from the 32nd Congress of the International Society on Thrombosis and...
Inflammation and immune interventions in MDS: targeting STAT, IRAK4, & more
In myelodysplastic syndromes (MDS), chronic inflammation driven by the innate immune system plays a key role in disease progression. Signal...
Updates in the treatment of SCD and thalassemia from EHA 2024: key trial updates, challenges with gene therapies & unmet needs
Todays VJHemOnc podcast features experts Rabi Hanna, MD, The Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, Subarna Chakravorty, MBBS, MRCPCH,...
Unmet treatment needs in MF: managing prefibrotic disease & thrombocytopenia, novel agents & endpoints for clinical trials
Myelofibrosis (MF) is a chronic myeloproliferative neoplasm (MPN) characterized by bone marrow fibrosis, extramedullary hematopoiesis, and splenomegaly, often resulting in...
The role of BTK inhibitors in MCL, ongoing trials & future outlooks: updates from EHA 2024
The introduction of Brutons tyrosine kinase (BTK) inhibitors into the treatment landscape for mantle cell lymphoma (MCL) has transformed the...
Visit Podcast Website
RSS Podcast Feed
Subscribe
Share
Add to MyCast